Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
ObsEva reports Q2 EPS (38c), consensus (42c) » 05:40
08/06/20
08/06
05:40
08/06/20
05:40
OBSV

ObsEva

$2.69 /

+ (+0.00%)

"The excellent phase…

"The excellent phase 3 results from PRIMROSE 1 and PRIMROSE 2 last month were critical achievements as we now embark upon regulatory filings and commercial preparation", said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva. "We strongly believe that our strategy to develop both a low dose of linzagolix without hormonal add back therapy and a high dose with hormonal add back therapy is the optimal way to treat more women suffering from heavy menstrual bleeding due to uterine fibroids."

ShowHide Related Items >><<
OBSV ObsEva
$2.69 /

+ (+0.00%)

OBSV ObsEva
$2.69 /

+ (+0.00%)

07/07/20 Wedbush
Selloff in ObsEva shares 'overdone,' says Wedbush
07/07/20 JPMorgan
JPMorgan downgrades ObsEva, cuts target to $5 from $18
07/07/20 JPMorgan
ObsEva downgraded to Neutral from Overweight at JPMorgan
07/06/20 BMO Capital
ObsEva downgraded to Market Perform from Outperform at BMO Capital
OBSV ObsEva
$2.69 /

+ (+0.00%)

OBSV ObsEva
$2.69 /

+ (+0.00%)

Over a month ago
Recommendations
Selloff in ObsEva shares 'overdone,' says Wedbush » 07:53
07/07/20
07/07
07:53
07/07/20
07:53
OBSV

ObsEva

$3.25 /

-2.9 (-47.15%)

Wedbush analyst Liana…

Wedbush analyst Liana Moussatos believes the selloff in ObsEva is "overdone." The analyst understands that investors are focused on the placebo-adjusted response rate observed in both PRIMROSE trials and minimized the importance of having a treatment for UF without having to add back estrogen to reduce bone loss. Of note, the Linzagolix 100 mg dose is the only oral GnRH dosing regimen being developed for UF without the need for ABT - a key differentiator. Moussatos considers ObsEva to be a buying opportunity right now due to what she believes is transiently negative investor sentiment. The analyst has an Outperform rating and a $30 price target on the shares.

ShowHide Related Items >><<
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

07/07/20 JPMorgan
JPMorgan downgrades ObsEva, cuts target to $5 from $18
07/07/20 JPMorgan
ObsEva downgraded to Neutral from Overweight at JPMorgan
07/06/20 BMO Capital
ObsEva downgraded to Market Perform from Outperform at BMO Capital
03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

Downgrade
JPMorgan downgrades ObsEva, cuts target to $5 from $18 » 06:14
07/07/20
07/07
06:14
07/07/20
06:14
OBSV

ObsEva

$3.25 /

-2.9 (-47.15%)

JPMorgan analyst Eric…

JPMorgan analyst Eric Joseph downgraded ObsEva to Neutral from Overweight with a price target of $5, down from $18. The analyst sees "renewed skepticism" on the regulatory path forward for the 100mg non-add back therapy linzagolix option, which he views as a central point of commercial differentiation within the greater oral gonadotropin-releasing hormone landscape. He moves to the sidelines pending further clinical and/or regulatory visibility.

ShowHide Related Items >><<
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

07/07/20 JPMorgan
ObsEva downgraded to Neutral from Overweight at JPMorgan
07/06/20 BMO Capital
ObsEva downgraded to Market Perform from Outperform at BMO Capital
03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 after pipeline update at Wedbush
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

Downgrade
ObsEva downgraded to Neutral from Overweight at JPMorgan » 05:43
07/07/20
07/07
05:43
07/07/20
05:43
OBSV

ObsEva

$3.25 /

-2.9 (-47.15%)

JPMorgan analyst Eric…

JPMorgan analyst Eric Joseph downgraded ObsEva to Neutral from Overweight with a $5 price target.

ShowHide Related Items >><<
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

07/06/20 BMO Capital
ObsEva downgraded to Market Perform from Outperform at BMO Capital
03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 after pipeline update at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 from $36 at Wedbush
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

Downgrade
ObsEva downgraded to Market Perform from Outperform at BMO Capital » 19:47
07/06/20
07/06
19:47
07/06/20
19:47
OBSV

ObsEva

$3.25 /

-2.9 (-47.15%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim downgraded ObsEva to Market Perform from Outperform with a price target of $4, down from $5, citing "mixed" Linzagolix PRIMROSE 1 results. The analyst notes that the data supports uterine fibroid use approval and his probability of success rises to 85% from 60%, but his estimates for high-dose Linzagolix+ABT use "looks similar to competitors" while being third to market. Kim also pushes out his launch estimate for the treatment by one year "to reflect filing timelines."

ShowHide Related Items >><<
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 after pipeline update at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 from $36 at Wedbush
12/19/19 H.C. Wainwright
ObsEva price target raised to $40 from $36 at H.C. Wainwright
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:14
07/06/20
07/06
16:14
07/06/20
16:14
UBER

Uber

$32.51 /

+1.85 (+6.03%)

, BRK.A

Berkshire Hathaway

$274,630.57 /

+6969.43 (+2.60%)

, BRK.B

Berkshire Hathaway

$182.78 /

+3.9 (+2.18%)

, D

Dominion

$73.60 /

-9.085 (-10.99%)

, DUK

Duke Energy

$79.81 /

-2.03 (-2.48%)

, T

AT&T

$30.51 /

+0.43 (+1.43%)

, ET

Energy Transfer LP

$6.25 /

-0.8 (-11.36%)

, REGN

Regeneron

$626.65 /

+5.89 (+0.95%)

, MSFT

Microsoft

$210.79 /

+4.52 (+2.19%)

, EA

Electronic Arts

$134.25 /

+0.55 (+0.41%)

, TTWO

Take-Two

$145.73 /

+1.37 (+0.95%)

, ATVI

Activision Blizzard

$78.68 /

+1.25 (+1.61%)

, CRTO

Criteo

$13.23 /

+1.84 (+16.15%)

, BDX

Becton Dickinson

$250.52 /

+5.43 (+2.22%)

, OBSV

ObsEva

$3.25 /

-2.9 (-47.15%)

, BLU

Bellus Health

$3.45 /

-8.56 (-71.27%)

U.S. stock markets were…

Open Full Text

ShowHide Related Items >><<
UBER Uber
$32.51 /

+1.85 (+6.03%)

TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

DUK Duke Energy
$79.81 /

-2.03 (-2.48%)

D Dominion
$73.60 /

-9.085 (-10.99%)

CRTO Criteo
$13.23 /

+1.84 (+16.15%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

BLU Bellus Health
$3.45 /

-8.56 (-71.27%)

BDX Becton Dickinson
$250.52 /

+5.43 (+2.22%)

ATVI Activision Blizzard
$78.68 /

+1.25 (+1.61%)

UBER Uber
$32.51 /

+1.85 (+6.03%)

07/07/20 KeyBanc
Uber acquisition of Postmates helps drive market rationalization, says KeyBanc
07/06/20 RBC Capital
Uber price target lowered to $45 from $52 at RBC Capital
07/06/20 Benchmark
Waitr Holdings price target raised to $5 from $4 at Benchmark
07/06/20 Wedbush
Uber's acquisition of Postmates 'a smart strategic move,' says Wedbush
BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

07/07/20 Argus
Dominion price target lowered to $80 from $87 at Argus
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
BRK.B Berkshire Hathaway
$182.78 /

+3.9 (+2.18%)

D Dominion
$73.60 /

-9.085 (-10.99%)

07/07/20 Mizuho
Dominion downgraded to Underperform from Neutral at Mizuho
07/07/20 Credit Suisse
Dominion downgraded to Neutral from Outperform at Credit Suisse
07/06/20 Wells Fargo
Wells says merits of Dominion's 'forward-looking' deal to be clearer with time
DUK Duke Energy
$79.81 /

-2.03 (-2.48%)

07/06/20 Stifel
ACP cancellation negative for mainline pipeline industry overall, says Stifel
07/06/20 JPMorgan
EQT could benefit from pipeline cancellation, says JPMorgan
T AT&T
$30.51 /

+0.43 (+1.43%)

06/25/20 BTIG
RingCentral price target raised to $325 from $275 at BTIG
06/15/20 Stephens
Electronic Arts seems like best fit as buyer for WB Interactive, says Stephens
06/15/20 Oppenheimer
EA makes 'most sense' as potential buyer of Warner gaming unit, says Oppenheimer
06/11/20 Wells Fargo
T-Mobile price target raised to $120 from $110 at Wells Fargo
ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

06/22/20 Citi
Energy Transfer LP price target lowered to $10 from $18 at Citi
06/09/20
Fly Intel: Top five analyst upgrades
06/09/20 BMO Capital
Energy Transfer LP upgraded to Outperform from Market Perform at BMO Capital
05/13/20 Bernstein
Energy Transfer LP price target lowered to $12 from $22 at Bernstein
REGN Regeneron
$626.65 /

+5.89 (+0.95%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

07/07/20 Loop Capital
Logitech price target raised to $78 from $58 at Loop Capital
07/06/20 Morgan Stanley
Microsoft skilling focus tempers some Pluralsight optimism, says Morgan Stanley
06/29/20 JMP Securities
ZoomInfo initiated with a Market Perform at JMP Securities
06/24/20 Bernstein
Potential spinoff would be largely positive for VMware, says Bernstein
EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

07/07/20 Oppenheimer
Electronic Arts price target raised to $150 from $125 at Oppenheimer
06/26/20 Needham
Electronic Arts price target raised to $150 from $135 at Needham
06/26/20 BMO Capital
Electronic Arts price target raised to $132 from $110 at BMO Capital
06/26/20 Stephens
Electronic Arts price target raised to $145 from $130 at Stephens
TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

06/12/20
Fly Intel: Top five analyst upgrades
06/12/20 MKM Partners
Take-Two upgraded to Buy after GTA V remaster announcement at MKM Partners
ATVI Activision Blizzard
$78.68 /

+1.25 (+1.61%)

07/07/20 Piper Sandler
Activision Blizzard price target raised to $86 from $79 at Piper Sandler
07/02/20 Needham
Activision Blizzard price target raised to $90 from $75 at Needham
07/01/20 BofA
BofA makes 14 additions, four deletions from US 1 list
06/29/20 Benchmark
Activision Blizzard price target raised to $85 from $77 at Benchmark
CRTO Criteo
$13.23 /

+1.84 (+16.15%)

06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
05/08/20 Deutsche Bank
Criteo price target lowered to $16 from $22 at Deutsche Bank
05/05/20 Truist
Criteo price target lowered to $13 from $25 at SunTrust
04/20/20 Nomura Instinet
Criteo price target lowered to $10 from $14 at Nomura Instinet
BDX Becton Dickinson
$250.52 /

+5.43 (+2.22%)

07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
06/01/20
Fly Intel: Top five analyst initiations
OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

07/07/20 Wedbush
Selloff in ObsEva shares 'overdone,' says Wedbush
07/07/20 JPMorgan
JPMorgan downgrades ObsEva, cuts target to $5 from $18
07/07/20 JPMorgan
ObsEva downgraded to Neutral from Overweight at JPMorgan
07/06/20 BMO Capital
ObsEva downgraded to Market Perform from Outperform at BMO Capital
BLU Bellus Health
$3.45 /

-8.56 (-71.27%)

07/07/20 Guggenheim
Guggenheim downgrades Bellus Health to Neutral after 'disappointing' cough trial
07/07/20 Guggenheim
Bellus Health downgraded to Neutral from Buy at Guggenheim
07/06/20 Jefferies
Jefferies cuts Bellus target to $6, sees potential for 'meaningful upside'
07/06/20 Mackie
Bellus Health downgraded to Hold from Speculative Buy at Mackie
UBER Uber
$32.51 /

+1.85 (+6.03%)

TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

DUK Duke Energy
$79.81 /

-2.03 (-2.48%)

D Dominion
$73.60 /

-9.085 (-10.99%)

CRTO Criteo
$13.23 /

+1.84 (+16.15%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

BDX Becton Dickinson
$250.52 /

+5.43 (+2.22%)

ATVI Activision Blizzard
$78.68 /

+1.25 (+1.61%)

  • 27
    May
  • 21
    May
  • 11
    Feb
  • 19
    Nov
  • 07
    Nov
  • 06
    Nov
  • 05
    Sep
UBER Uber
$32.51 /

+1.85 (+6.03%)

TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

D Dominion
$73.60 /

-9.085 (-10.99%)

BRK.B Berkshire Hathaway
$182.78 /

+3.9 (+2.18%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

UBER Uber
$32.51 /

+1.85 (+6.03%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

D Dominion
$73.60 /

-9.085 (-10.99%)

CRTO Criteo
$13.23 /

+1.84 (+16.15%)

BRK.B Berkshire Hathaway
$182.78 /

+3.9 (+2.18%)

BRK.A Berkshire Hathaway
$274,630.57 /

+6969.43 (+2.60%)

BDX Becton Dickinson
$250.52 /

+5.43 (+2.22%)

UBER Uber
$32.51 /

+1.85 (+6.03%)

TTWO Take-Two
$145.73 /

+1.37 (+0.95%)

T AT&T
$30.51 /

+0.43 (+1.43%)

REGN Regeneron
$626.65 /

+5.89 (+0.95%)

OBSV ObsEva
$3.25 /

-2.9 (-47.15%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

ET Energy Transfer LP
$6.25 /

-0.8 (-11.36%)

EA Electronic Arts
$134.25 /

+0.55 (+0.41%)

DUK Duke Energy
$79.81 /

-2.03 (-2.48%)

D Dominion
$73.60 /

-9.085 (-10.99%)

ATVI Activision Blizzard
$78.68 /

+1.25 (+1.61%)

MSFT Microsoft
$210.79 /

+4.52 (+2.19%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:02
07/06/20
07/06
12:02
07/06/20
12:02
UBER

Uber

$32.46 /

+1.8 (+5.87%)

, D

Dominion

$75.70 /

-6.98 (-8.44%)

, DUK

Duke Energy

$79.60 /

-2.24 (-2.74%)

, BRK.A

Berkshire Hathaway

$273,400.00 /

+5738.86 (+2.14%)

, REGN

Regeneron

$636.28 /

+15.52 (+2.50%)

, CRTO

Criteo

$13.53 /

+2.14 (+18.79%)

, BDX

Becton Dickinson

$252.66 /

+7.57 (+3.09%)

, BLU

Bellus Health

$2.71 /

-9.3 (-77.44%)

, OBSV

ObsEva

$3.34 /

-2.81 (-45.69%)

U.S. stock markets are…

Open Full Text

ShowHide Related Items >><<
UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

OBSV ObsEva
$3.34 /

-2.81 (-45.69%)

DUK Duke Energy
$79.60 /

-2.24 (-2.74%)

D Dominion
$75.70 /

-6.98 (-8.44%)

CRTO Criteo
$13.53 /

+2.14 (+18.79%)

BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

BLU Bellus Health
$2.71 /

-9.3 (-77.44%)

BDX Becton Dickinson
$252.66 /

+7.57 (+3.09%)

UBER Uber
$32.46 /

+1.8 (+5.87%)

07/06/20 Benchmark
Waitr Holdings price target raised to $5 from $4 at Benchmark
07/06/20 Wedbush
Uber's acquisition of Postmates 'a smart strategic move,' says Wedbush
07/01/20 BTIG
Uber consensus likely aggressive, says BTIG
06/30/20 Truist
Uber shouldn't face regulatory issues if it buys Postmates, says Suntrust
D Dominion
$75.70 /

-6.98 (-8.44%)

07/06/20 JPMorgan
EQT could benefit from pipeline cancellation, says JPMorgan
07/06/20 JPMorgan
Dominion now positioned as 'best-in-class' utility, says JPMorgan
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
06/09/20 Seaport Global
Dominion initiated with a Buy at Seaport Global
DUK Duke Energy
$79.60 /

-2.24 (-2.74%)

06/09/20 Seaport Global
Duke Energy initiated with a Neutral at Seaport Global
05/20/20 Wells Fargo
Duke Energy price target lowered to $88 from $108 at Wells Fargo
BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
REGN Regeneron
$636.28 /

+15.52 (+2.50%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
CRTO Criteo
$13.53 /

+2.14 (+18.79%)

06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
05/08/20 Deutsche Bank
Criteo price target lowered to $16 from $22 at Deutsche Bank
05/05/20 Truist
Criteo price target lowered to $13 from $25 at SunTrust
04/20/20 Nomura Instinet
Criteo price target lowered to $10 from $14 at Nomura Instinet
BDX Becton Dickinson
$252.66 /

+7.57 (+3.09%)

07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
06/01/20
Fly Intel: Top five analyst initiations
BLU Bellus Health
$2.71 /

-9.3 (-77.44%)

07/06/20 H.C. Wainwright
H.C. Wainwright reiterates $28 target on Bellus despite Phase 2 miss
06/26/20 H.C. Wainwright
Bellus Health initiated with a Buy at H.C. Wainwright
01/08/20 Guggenheim
Horizon Therapeutics named Guggenheim's best Emerging Pharma idea for 2020
09/30/19
Fly Intel: Top five analyst initiations
OBSV ObsEva
$3.34 /

-2.81 (-45.69%)

03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 after pipeline update at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 from $36 at Wedbush
12/19/19 H.C. Wainwright
ObsEva price target raised to $40 from $36 at H.C. Wainwright
UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

OBSV ObsEva
$3.34 /

-2.81 (-45.69%)

DUK Duke Energy
$79.60 /

-2.24 (-2.74%)

D Dominion
$75.70 /

-6.98 (-8.44%)

CRTO Criteo
$13.53 /

+2.14 (+18.79%)

BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

BDX Becton Dickinson
$252.66 /

+7.57 (+3.09%)

  • 27
    May
  • 21
    May
  • 11
    Feb
  • 19
    Nov
  • 07
    Nov
  • 06
    Nov
  • 05
    Sep
UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

D Dominion
$75.70 /

-6.98 (-8.44%)

BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

D Dominion
$75.70 /

-6.98 (-8.44%)

CRTO Criteo
$13.53 /

+2.14 (+18.79%)

BRK.A Berkshire Hathaway
$273,400.00 /

+5738.86 (+2.14%)

BDX Becton Dickinson
$252.66 /

+7.57 (+3.09%)

UBER Uber
$32.46 /

+1.8 (+5.87%)

REGN Regeneron
$636.28 /

+15.52 (+2.50%)

OBSV ObsEva
$3.34 /

-2.81 (-45.69%)

DUK Duke Energy
$79.60 /

-2.24 (-2.74%)

D Dominion
$75.70 /

-6.98 (-8.44%)

On The Fly
Fly Intel: Pre-market Movers » 09:06
07/06/20
07/06
09:06
07/06/20
09:06
UBER

Uber

$30.66 /

+0.24 (+0.79%)

, REGN

Regeneron

$620.76 /

+11.54 (+1.89%)

, BDX

Becton Dickinson

$245.09 /

+3.57 (+1.48%)

, SBH

Sally Beauty

$13.08 /

+0.17 (+1.32%)

, DTIL

Precision BioSciences

$8.44 /

+0.06 (+0.72%)

, SLCA

U.S. Silica

$3.36 /

+0.05 (+1.51%)

, SPOT

Spotify

$271.59 /

+12.63 (+4.88%)

, D

Dominion

$82.68 /

+0.32 (+0.39%)

, OBSV

ObsEva

$6.15 /

+0.17 (+2.84%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

SLCA U.S. Silica
$3.36 /

+0.05 (+1.51%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

D Dominion
$82.68 /

+0.32 (+0.39%)

BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

UBER Uber
$30.66 /

+0.24 (+0.79%)

07/06/20 Wedbush
Uber's acquisition of Postmates 'a smart strategic move,' says Wedbush
07/01/20 BTIG
Uber consensus likely aggressive, says BTIG
06/30/20 Truist
Uber shouldn't face regulatory issues if it buys Postmates, says Suntrust
06/25/20 Deutsche Bank
Yandex interest in Uber's minority stake modest positive, says Deutsche Bank
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
06/01/20
Fly Intel: Top five analyst initiations
SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

06/04/20 Oppenheimer
Sally Beauty upgraded to Outperform at Oppenheimer
06/04/20 Oppenheimer
Sally Beauty upgraded to Outperform from Perform at Oppenheimer
04/27/20 DA Davidson
Sally Beauty price target lowered to $10 from $14.50 at DA Davidson
04/20/20 Raymond James
Sally Beauty preliminary Q2 not as bad as feared, says Raymond James
DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
SLCA U.S. Silica
$3.36 /

+0.05 (+1.51%)

07/06/20 Evercore ISI
U.S. Silica upgraded to In Line from Underperform at Evercore ISI
03/19/20 Barclays
U.S. Silica upgraded to Equal Weight from Underweight at Barclays
03/11/20 Tudor Pickering
U.S. Silica downgraded to Hold from Buy at Tudor Pickering
03/09/20 Evercore ISI
U.S. Silica downgraded to Underperform from Outperform at Evercore ISI
SPOT Spotify
$271.59 /

+12.63 (+4.88%)

07/06/20 JPMorgan
Spotify price target raised to $305 from $185 at JPMorgan
07/06/20 Bernstein
Bernstein doubts Spotify will make money off podcasts, downgrades to sell
07/06/20 Bernstein
Spotify downgraded to Underperform from Market Perform at Bernstein
07/01/20 Wells Fargo
Spotify price target raised to $175 from $130 at Wells Fargo
D Dominion
$82.68 /

+0.32 (+0.39%)

07/06/20 JPMorgan
EQT could benefit from pipeline cancellation, says JPMorgan
07/06/20 JPMorgan
Dominion now positioned as 'best-in-class' utility, says JPMorgan
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
06/09/20 Seaport Global
Dominion initiated with a Buy at Seaport Global
OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 after pipeline update at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 from $36 at Wedbush
12/19/19 H.C. Wainwright
ObsEva price target raised to $40 from $36 at H.C. Wainwright
UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

SLCA U.S. Silica
$3.36 /

+0.05 (+1.51%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

D Dominion
$82.68 /

+0.32 (+0.39%)

BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

  • 27
    May
  • 21
    May
  • 11
    Feb
  • 07
    Nov
  • 06
    Nov
UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

D Dominion
$82.68 /

+0.32 (+0.39%)

UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

D Dominion
$82.68 /

+0.32 (+0.39%)

BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

D Dominion
$82.68 /

+0.32 (+0.39%)

Conference/Events
ObsEva to host conference call » 07:55
07/06/20
07/06
07:55
07/06/20
07:55
OBSV

ObsEva

$6.15 /

+0.17 (+2.84%)

Management holds a…

Management holds a conference call to discuss results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials evaluating Linzagolix will be held on July 6 at 8 am. Webcast Link

ShowHide Related Items >><<
OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 after pipeline update at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 from $36 at Wedbush
12/19/19 H.C. Wainwright
ObsEva price target raised to $40 from $36 at H.C. Wainwright
OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

Hot Stocks
ObsEva says PRIMROSE 1 study of Yselty met primary endpoint » 05:42
07/06/20
07/06
05:42
07/06/20
05:42
OBSV

ObsEva

$6.15 /

+0.17 (+2.84%)

ObsEva announced top-line…

ObsEva announced top-line results from the PRIMROSE 1 and 2 studies of Yselty to assess the efficacy and safety in women with heavy menstrual bleeding due to uterine fibroids. ObsEva said in a release, "PRIMROSE 1 met the primary endpoint at week 24, and showed that women receiving linzagolix experienced a statistically significant and clinically meaningful reduction in menstrual blood loss compared to placebo. Women receiving 200 mg with ABT achieved a 75.5% responder rate and those receiving 100 mg without ABT achieved a 56.4% responder rate. The pooled week 24 data from these two Phase 3 studies support a best-in-class profile, with a responder rate of 84.7% in women receiving linzagolix 200 mg with ABT, and 56.6% in women receiving linzagolix 100 mg without ABT. In addition, new data from PRIMROSE 2 demonstrate that continued treatment with linzagolix for 52 weeks provides sustained efficacy and is well tolerated. Responder rates of 91.6% and 53.2% were observed in women receiving 200 mg with ABT and 100 mg without ABT, respectively, both of which are similar to the responder rates observed at week 24 of the study. Across both studies, women receiving linzagolix experienced statistically significant improvements across a number of clinically relevant secondary endpoints, including reduction in pain, improvement in anemia and quality of life. In PRIMROSE 1, the incidence of adverse events was similar between placebo and active treatment. The most frequently observed adverse events, with an incidence greater than 5%, were headache and hot flushes. In addition, a minimal mean percentage change in lumbar spine bone mineral density, or BMD, from baseline was observed in both treatment arms at week 24. In PRIMROSE 2, the most frequently observed adverse events, with an incidence greater than 5%, were headache, hot flushes and anemia. In addition, a small incremental change in BMD was observed at week 52 compared to week 24. ObsEva is now preparing its regulatory submissions to the European Medicines Agency and the FDA which it anticipates submitting in 4Q 2020 and 1H 2021, respectively. Data from across the clinical trial program will be submitted for presentation at upcoming scientific conferences."

ShowHide Related Items >><<
OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 after pipeline update at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 from $36 at Wedbush
12/19/19 H.C. Wainwright
ObsEva price target raised to $40 from $36 at H.C. Wainwright
OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.